Ignite Creation Date:
2025-12-25 @ 3:08 AM
Ignite Modification Date:
2026-05-19 @ 8:01 AM
Study NCT ID:
NCT02189733
Status:
COMPLETED
Last Update Posted:
2014-11-14
First Post:
2014-07-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Sponsor:
Ablynx, a Sanofi company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ALX0681-C102
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None